PMID- 32764479
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 8
DP  - 2020 Aug 5
TI  - YB-1 Mediates TNF-Induced Pro-Survival Signaling by Regulating NF-kappaB Activation.
LID - 10.3390/cancers12082188 [doi]
LID - 2188
AB  - Cell fate decisions regulating survival and death are essential for maintaining 
      tissue homeostasis; dysregulation thereof can lead to tumor development. In some 
      cases, survival and death are triggered by the same receptor, e.g., tumor 
      necrosis factor (TNF)-receptor 1 (TNFR1). We identified a prominent role for the 
      cold shock Y-box binding protein-1 (YB-1) in the TNF-induced activation and 
      nuclear translocation of nuclear factor kappa-light-chain-enhancer of activated B 
      cells (NF-kappaB) p65. In the absence of YB-1, the expression of TNF 
      receptor-associated factor 2 (TRAF2), a central component of the TNF receptor 
      signaling complex required for NF-kappaB activation, is significantly reduced. 
      Therefore, we hypothesized that the loss of YB-1 results in a destabilization of 
      TRAF2. Consistent with this hypothesis, we observed that YB-1-deficient cells 
      were more prone to TNF-induced apoptotic cell death. We observed enhanced 
      effector caspase-3 activation and could successfully rescue the cells using the 
      pan-caspase inhibitor zVAD-fmk, but not necrostatin-1. Taken together, our 
      results indicate that YB-1 plays a central role in promoting cell survival 
      through NF-kappaB activation and identifies a novel mechanism by which enhanced YB-1 
      expression may contribute to tumor development.
FAU - Shah, Aneri
AU  - Shah A
AD  - Clinic of Nephrology and Hypertension, Diabetes and Endocrinology, 
      Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.
FAU - Plaza-Sirvent, Carlos
AU  - Plaza-Sirvent C
AD  - Institute for Molecular and Clinical Immunology, Otto-von-Guericke University 
      Magdeburg, 39120 Magdeburg, Germany.
AD  - Systems-Oriented Immunology and Inflammation Research Group, Department of 
      Experimental Immunology, Helmholtz Centre for Infection Research, 38124 
      Braunschweig, Germany.
AD  - Department of Molecular Immunology, ZKF2, Ruhr-University Bochum, D-44780 Bochum, 
      Germany.
FAU - Weinert, Sonke
AU  - Weinert S
AUID- ORCID: 0000-0002-7201-0836
AD  - Department of Cardiology and Angiology, Otto-von-Guericke University Magdeburg, 
      39120 Magdeburg, Germany.
FAU - Buchbinder, Jorn H
AU  - Buchbinder JH
AD  - Translational Inflammation Research, Institute of Experimental Internal Medicine, 
      Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.
FAU - Lavrik, Inna N
AU  - Lavrik IN
AD  - Translational Inflammation Research, Institute of Experimental Internal Medicine, 
      Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.
FAU - Mertens, Peter R
AU  - Mertens PR
AD  - Clinic of Nephrology and Hypertension, Diabetes and Endocrinology, 
      Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.
FAU - Schmitz, Ingo
AU  - Schmitz I
AUID- ORCID: 0000-0002-5360-0419
AD  - Institute for Molecular and Clinical Immunology, Otto-von-Guericke University 
      Magdeburg, 39120 Magdeburg, Germany.
AD  - Systems-Oriented Immunology and Inflammation Research Group, Department of 
      Experimental Immunology, Helmholtz Centre for Infection Research, 38124 
      Braunschweig, Germany.
AD  - Department of Molecular Immunology, ZKF2, Ruhr-University Bochum, D-44780 Bochum, 
      Germany.
FAU - Lindquist, Jonathan A
AU  - Lindquist JA
AUID- ORCID: 0000-0001-6846-5056
AD  - Clinic of Nephrology and Hypertension, Diabetes and Endocrinology, 
      Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany.
LA  - eng
GR  - Project-ID 97850925 - SFB 854: Project A1 to PRM and project A23 to IS, as well 
      as GRK 2408, project 8, grants ME-1365/7-2 and ME-1365/9-2 to PRM, LA-2386/6-1 to 
      IL, and LI-1031/4-1 to JAL/Deutsche Forschungsgemeinschaft/
GR  - project number ZS/2016/08/80645/federal state Saxony-Anhalt and the European 
      Structural and Investment Funds (ESF, 2014-2020)/
PT  - Journal Article
DEP - 20200805
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7464034
OTO - NOTNLM
OT  - TNF
OT  - apoptosis
OT  - cold shock proteins
COIS- The authors declare no conflict of interest. The funding agencies had no role in 
      the study design; in the collection, analyses, or interpretation of data; in the 
      writing of the manuscript; or in the decision to publish.
EDAT- 2020/08/09 06:00
MHDA- 2020/08/09 06:01
PMCR- 2020/08/05
CRDT- 2020/08/09 06:00
PHST- 2020/06/23 00:00 [received]
PHST- 2020/07/25 00:00 [revised]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/08/09 06:00 [entrez]
PHST- 2020/08/09 06:00 [pubmed]
PHST- 2020/08/09 06:01 [medline]
PHST- 2020/08/05 00:00 [pmc-release]
AID - cancers12082188 [pii]
AID - cancers-12-02188 [pii]
AID - 10.3390/cancers12082188 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Aug 5;12(8):2188. doi: 10.3390/cancers12082188.